Skip to main content
FDA Approvals
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
Read More
FDA Approvals
The Hematology Pipeline Features New Immune Therapies, and Targeted Agents
Wayne Kuznar
Read More
Perspectives
Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value
James T. Kenney, RPh, MBA
Read More
FDA Approvals
CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
Phoebe Starr
Read More
Practice Management
Induction Therapy plus Autologous Stem-Cell Transplantation Still Cost-Effective for Newly Diagnosed Multiple Myeloma
Chase Doyle
Read More
Lymphoma
Obinutuzumab Prolongs Survival in Follicular Lymphoma
Phoebe Starr
Read More
Page 3 of 3
Results 21 - 27 of 27